ClinicalTrials.gg
RecruitingNCT05442567Updated May 7, 2026

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

A Phase 3 interventional study of Vedolizumab IV and No Intervention in Ulcerative Colitis and Crohn's Disease, sponsored by Takeda. Recruiting at 98 sites in 18 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Planned enrollment
13th of 38
240 · median 110
Started
2023
the only one that year
Phase 3
14 of 38
3 open now
Registered
30th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 13th largest by planned enrollment, is the only one that started in 2023, is one of 14 in phase 3, and was the 30th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

Read the detailed description

This multi-center trial is conducted worldwide. Up to 240 patients would be enrolled from Studies MLN0002-3024 [participants with UC] and MLN0002-3025 [participants with CD], either in the Treatment Cohort or in the Observational Cohort. Approximately 93 participants who have previously participated either in study MLN0002-3024 or MLN0002-3025, referred to as parent study, are expected to roll over to the MLN0002-3029 study in the treatment cohort.

Treatment Cohort:

The drug being tested in this study is called vedolizumab, being studied to treat pediatric patients who have UC or CD.

Participants eligible for the Treatment Cohort can be administered vedolizumab intravenous (IV) at Week 54 visit of parent study or up to 1 week after Week 54 of the parent study based on the availability of test results needed to assess eligibility of the participant. At this study entry, participants will be administered the same blinded dose of vedolizumab IV that was received at Week 46 in the parent study and will then continue to receive vedolizumab IV at a frequency of once every 8 weeks (Q8W) in the following treatment groups:

  • Participants 10 to ≤15 kilogram (kg), Vedolizumab 150 milligram (mg) (High dose)
  • Participants 10 to ≤15 kg, Vedolizumab 100 mg (Low dose)
  • Participants >15 to \<30 kg, Vedolizumab 200 mg (High dose)
  • Participants >15 to \<30 kg, Vedolizumab 100 mg (Low dose)
  • Participants ≥30 kg, Vedolizumab 300 mg (High dose)
  • Participants ≥30 kg, Vedolizumab 150 mg (Low dose)

Blinding of dose group assignment of the parent study will continue until the respective parent study is unblinded in order to protect the blinding of the parent study.

The overall time to participate in the Treatment Cohort of this study is up to participant withdrawal, or until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first. Participants who complete or are discontinued from the study for any reason will complete the final safety/end of study (EOS) visit 18 weeks after their last dose of study drug.

Observational Cohort:

Participants who received at least 1 dose of study drug during parent study and early terminated or are not eligible for the Treatment Cohort of this study after completion of the Week 54 visit of parent study, will be enrolled in the Observational Cohort of this study as part of a long-term follow-up period to assess prespecified safety events of interest and will not receive continued treatment with vedolizumab IV.

The overall time to participate in the Observational Cohort is up to approximately 2 years.

03

Conditions studied

  • Ulcerative Colitis
  • Crohn's Disease

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

For Treatment Cohort:

  1. The participant should have completed Study MLN0002-3024 or Study MLN0002-3025 and achieved -free clinical response at Week 54 (and has tapered off of steroids, as applicable, at least 12 weeks before Week 54) as defined by a reduction of partial Mayo score of ≥2 points and ≥25% from baseline for participants with UC, or by a decrease of pediatric Crohn's disease activity index (PCDAI) of ≥15 points for participants with CD and with total PCDAI ≤30.
  2. A male participant who is sexually active with a female partner of agrees to use a barrier method of (e.g., condom with or without spermicide) from signing of participant/parental and/or pediatric assent throughout the duration of the study and for 18 weeks after last dose. The female partner of a male participant should also be advised to use a highly effective method of contraception.
  3. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use a highly effective method of contraception from signing of participant/parental informed consent and/or pediatric assent throughout the duration of the study and 18 weeks after the last dose.

For Observational Cohort:

1. The participant has received at least 1 dose of vedolizumab during Study MLN0002-3024 or Study MLN0002-3025 and early terminated OR completed the Week 54 visit of Study MLN0002-3024 or Study MLN0002-3025 but was not eligible to enroll in the treatment cohort of this study.

Main Exclusion Criteria:

For Treatment Cohort only:

  1. The participant currently requires major surgical intervention for UC or CD (e.g., bowel resection), or is anticipated to require major surgical intervention for UC or CD during the study.
  2. The participant has developed any new unstable or uncontrolled cardiovascular, heart failure moderate to severe (New York Class Association III or IV), pulmonary, hepatic, renal, gastrointestinal (GI), genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurological, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.
  3. The participant has other serious comorbidities that will limit their ability to complete the study.
  4. The participant is unable to comply with all study assessments.
  5. The participant has or allergies to any of the vedolizumab .
  6. The participant is lactating or pregnant.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 150 mg

    Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.

    Drug: Vedolizumab IV

  • Experimental
    Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 100 mg

    Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.

    Drug: Vedolizumab IV

  • Experimental
    Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 200 mg

    Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing \>15 to \<30 kg will receive vedolizumab 200 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.

    Drug: Vedolizumab IV

  • Experimental
    Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 100 mg

    Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing \>15 to \<30 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.

    Drug: Vedolizumab IV

  • Experimental
    Treatment Cohort: Participants ≥30 kg, Vedolizumab 300 mg

    Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 300 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.

    Drug: Vedolizumab IV

  • Experimental
    Treatment Cohort: Participants ≥30 kg, Vedolizumab 150 mg

    Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.

    Drug: Vedolizumab IV

  • Other
    Observational Cohort: Early Terminated Participants From Parent Studies

    Participants will have assessment visits at Day 1 and Weeks 8, 34, 60, and 86 as part of a long-term follow-up period to assess prespecified safety events of interest and to monitor growth and pubertal development for approximately 2 years after their last dose of study drug in parent study.

    Other: No Intervention

Interventions

  • Vedolizumab IV infusion

    Also known as: MLN0002, ENTYVIO, KYNTELES

  • OtherNo Intervention

    Participants will not receive any intervention in the Observational Cohort.

06

What researchers measure

Primary outcomes

  1. Treatment Cohort: Number of Participants With at Least One Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have causal relationship with this treatment. AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to drug.

    Time frame: From first dose of study drug up to approximately 5 years

  2. Observational Cohort: Number of Participants With Prespecified Safety Events

    Prespecified safety events will include serious infections, malignancies, progressive multifocal leukoencephalopathy (PML), concerns about growth and pubertal development, and bowel surgery.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Treatment Cohort: Time to Major Inflammatory Bowel Disease (IBD)-related Events

    Major IBD-related events include hospitalizations, surgeries, and procedures in pediatric participants with UC or CD.

    Time frame: Up to approximately 5 years

  2. Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Total Score for Participants Aged 9 to 17 Years for Every 24 Weeks

    The IMPACT-III questionnaire is a self-reported measure with 35 closed questions encompassing 6 domains: Bowel Symptoms (7 items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), Treatment/Interventions (3 items), and Emotional Functioning (7 items). The IMPACT-III uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The total score is an average of all item scores. The outcome score ranges from 35 to 175, with higher scores suggesting better quality of life. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.

    Time frame: Baseline, every 24 weeks in this study (up to approximately 5 years)

  3. Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Bowel Symptom Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks

    The IMPACT-III Bowel Symptom Subscale is a self-reported measure with 7 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The bowel symptom subscale score ranges from 1 to 35, with higher scores indicating lesser bowel symptoms. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.

    Time frame: Baseline, every 24 weeks in this study (up to approximately 5 years)

  4. Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Systemic Symptom Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks

    The IMPACT-III Systemic Symptom Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The Systemic symptom subscale score ranges from 1 to 15, with higher scores indicating lesser systemic symptoms. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.

    Time frame: Baseline, every 24 weeks in this study (up to approximately 5 years)

  5. Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Social Functioning Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks

    The IMPACT-III Social Functioning Subscale is a self-reported measure with 12 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The social functioning subscale score ranges from 1 to 60, with higher scores indicating better social functioning. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.

    Time frame: Baseline, every 24 weeks in this study (up to approximately 5 years)

  6. Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Body Image Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks

    The IMPACT-III Body Image Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The body image subscale score ranges from 1 to 15, with higher scores indicating better body image. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.

    Time frame: Baseline, every 24 weeks in this study (up to approximately 5 years)

  7. Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Treatment/Intervention Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks

    The IMPACT-III Treatment/Intervention Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The treatment/intervention subscale score ranges from 1 to 15, with higher scores indicating ease of administration of treatment/interventions. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.

    Time frame: Baseline, every 24 weeks in this study (up to approximately 5 years)

  8. Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Emotional Functioning Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks

    The IMPACT-III Emotional Functioning Subscale is a self-reported measure with 7 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The emotional functioning subscale score ranges from 1 to 35, with higher scores indicating better emotional functioning. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025.

    Time frame: Baseline, every 24 weeks in this study (up to approximately 5 years)

07

Study locations

44 of 98 sites recruiting
  • University of South Alabama (USA) Physicians Group
    Mobile, Alabama 36604, United States
    Not yet recruiting
    • Site Contact · Contact
    • David Gremse · Principal investigator
  • Phoenix Childrens Hospital - Thomas Rd - PIN
    Phoenix, Arizona 85016, United States
    Recruiting
    • Site Contact · Contact
    • Ashish Patel · Principal investigator
  • Cedars Sinai Medical Center - 127 San Vicente Blvd
    Los Angeles, California 90048, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Rady Children's Hospital - San Diego - PIN
    San Diego, California 92123, United States
    Not yet recruiting
    • Site Contact · Contact
    • Jeannie Huang · Principal investigator
  • University of California San Francisco
    San Francisco, California 94158, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • I.H.S Health LLC-Kissimmee-445 W Oak St
    Kissimmee, Florida 34741, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Childrens Center For Digestive Healthcare
    Atlanta, Georgia 30342, United States
    Not yet recruiting
    • Site Contact · Contact
    • Benjamin Gold · Principal investigator
  • Advocate Children's Hospital - Park Ridge - PIN
    Park Ridge, Illinois 60068, United States
    Recruiting
    • Site Contact · Contact
    • Kiranmai Gorla · Principal investigator
  • Riley Hospital For Children - PIN
    Indianapolis, Indiana 46202, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Boston Children's Hospital - PIN
    Boston, Massachusetts 02215, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • MNGI Digestive Health PA-Plymouth
    Minneapolis, Minnesota 55413, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Mayo Clinic - PIN
    Rochester, Minnesota 55905, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Goryeb Children's Hospital
    Morristown, New Jersey 07960, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Cohen Children's Medical Center Northwell - BRANY - PPDS - PIN
    New Hyde Park, New York 11042, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Rochester Medical Center - PPDS
    Rochester, New York 14642, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Hospitals Cleveland Medical Center - 11100 Euclid Ave
    Cleveland, Ohio 44106, United States
    Not yet recruiting
    • Site Contact · Contact
    • Thomas Sferra · Principal investigator
  • UPMC Children's Hospital of Pittsburgh - Adolescent Medicine (Oakland) - PIN
    Pittsburgh, Pennsylvania 15201, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hasbro Children's Hospital - PIN
    Providence, Rhode Island 02903, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Texas Children's Hospital - Baylor - PIN
    Houston, Texas 77030, United States
    Not yet recruiting
    • Site Contact · Contact
    • Faith Ihekweazu · Principal investigator
  • Carilion Children's Tanglewood Center
    Roanoke, Virginia 24018, United States
    Recruiting
    • Site Contact · Contact
    • Monica Garin-Laflam · Principal investigator
  • Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Site Contact · Contact
    • Shoma Dutt · Principal investigator
  • Queensland Childrens Hospital
    South Brisbane, Queensland 4101, Australia
    Recruiting
    • Site Contact · Contact
    • Christopher Burgess · Principal investigator
  • Monash Health, Monash Medical Centre
    Clayton, Victoria 3168, Australia
    Not yet recruiting
    • Site Contact · Contact
    • Edward Giles · Principal investigator
  • Royal Children's Hospital Melbourne - PIN
    Parkville, Victoria 3052, Australia
    Recruiting
    • Site Contact · Contact
    • George Alex · Principal investigator
  • UZ Antwerpen - PIN
    Edegem, Antwerpen 2650, Belgium
    Recruiting
    • Site Contact · Contact
    • Els Van de Vijver · Principal investigator
  • UZ Brussel - PIN
    Jette, Brussels Capital 1090, Belgium
    Recruiting
    • Site Contact · Contact
    • Elisabeth De Greef · Principal investigator
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
    Recruiting
    • Site Contact · Contact
    • Ilse Hoffman · Principal investigator
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • British Columbia Children's Hospital - 4480 Oak St
    Vancouver, British Columbia V6H 3N1, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • London Health Sciences Centre -800 Commissioners Rd E
    London, Ontario N6A 5W9, Canada
    Terminated

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Universitaire Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Beijing Children's Hospital, Capital Medical University - PIN
    Beijing, Beijing Municipality 100045, China
    Not yet recruiting
    • Site Contact · Contact
    • Jie Wu · Principal investigator
  • Henan Children's Hospital Zhengzhou Children's Hospital - Zhengdong Campus
    Zhengzhou, Henan 450018, China
    Recruiting
    • Site Contact · Contact
    • Xiaoqin Li · Principal investigator
  • Hunan Children's Hospital
    Changsha, Hunan 410007, China
    Recruiting
    • Site Contact · Contact
    • Hongmei Zhao · Principal investigator
  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality 201102, China
    Recruiting
    • Site Contact · Contact
    • Ying Huang · Principal investigator
  • The Children's Hospital Zhejiang University School of Medicine - Binjiang Campus
    Hangzhou, Zhejiang 310003, China
    Recruiting
    • Site Contact · Contact
    • Jie Chen · Principal investigator
  • Children's Hospital Zagreb
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
    • Site Contact · Contact
    • Iva Hojsak · Principal investigator
  • University Hospital Center Zagreb
    Zagreb, City of Zagreb 10000, Croatia
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Hospital of Split-Spinciceva 1
    Split, 21000, Croatia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Fakultni nemocnice Kralovske Vinohrady
    Prague, Praha, Hlavni Mesto 100 34, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Fakultni Thomayerova Nemocnice
    Prague, Praha, Hlavni Mesto 140 00, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • University General Hospital ''ATTIKON'' - General Hospital of West Attica H AGIA VARVARA
    Athens, Attica 12462, Greece
    Recruiting
    • Site Contact · Contact
    • Smaragdi Fessatou · Principal investigator
  • Children's Hospital Agia Sofia
    Athens, GR11527, Greece
    Recruiting
    • Site Contact · Contact
    • Alexandra Papadopoulou · Principal investigator
  • General Hospital of Thessaloniki ''Hippokratio''
    Thessaloniki, 546 42, Greece
    Withdrawn

    Not enrolling at this site — choose another above.

  • General Hospital of Thessaloniki ''Hippokratio''
    Thessaloniki, 546 42, Greece
    Recruiting
    • Site Contact · Contact
    • Ioannis Xinias · Principal investigator
  • Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz
    Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
    Recruiting
    • Site Contact · Contact
    • Erzsebet Szakos · Principal investigator
  • Szegedi Tudomanyegyetem, SZAKK, Borgyogyaszati es Allergologiai Klinika
    Szeged, Csongrád megye 6720, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinexpert Obuda Egeszsegcentruma
    Budapest, 1033, Hungary
    Terminated

    Not enrolling at this site — choose another above.

  • Semmelweis Egyetem, Pulmonologiai Klinika
    Budapest, 1083, Hungary
    Recruiting
    • Site Contact · Contact
    • Aron Cseh · Principal investigator
  • Tel Aviv Sourasky Medical Center Ichilov - PPDS
    Jerusalem, Jerusalem 90000, Israel
    Recruiting
    • Site Contact · Contact
    • Shlomi Cohen · Principal investigator
  • Shaare Zedek Medical Center
    Jerusalem, Jerusalem 91031, Israel
    Recruiting
    • Site Contact · Contact
    • Dan Turner · Principal investigator
  • Soroka University Medical Centre
    Beersheba, 84101, Israel
    Withdrawn

    Not enrolling at this site — choose another above.

  • Rambam Health Care Campus PPDS
    Haifa, 31096, Israel
    Recruiting
    • Site Contact · Contact
    • Ron Shaoul · Principal investigator
  • Carmel Medical Center
    Haifa, 34362, Israel
    Recruiting
    • Site Contact · Contact
    • Reut Batcir · Principal investigator
  • Hadassah Medical Center- Ein Kerem - PPDS
    Jerusalem, 91120, Israel
    Recruiting
    • Site Contact · Contact
    • Zev Davidovics · Principal investigator
  • Schneider Childrens Medical Center of Israel Petah Tikvah PIN
    Petah Tikva, 49100, Israel
    Terminated

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Universitaria Federico II
    Naples, Campania 80131, Italy
    Recruiting
    • Site Contact · Contact
    • Erasmo Miele · Principal investigator
  • Azienda Ospedaliera Universitaria Luigi Vanvitelli - Piazza Luigi Miraglia 2
    Naples, Campania 80131, Italy
    Recruiting
    • Site Contact · Contact
    • Caterina Strisciuglio · Principal investigator
  • Azienda USL di Bologna
    Bologna, Emilia-Romagna 40133, Italy
    Recruiting
    • Site Contact · Contact
    • Patrizia Alvisi · Principal investigator
  • Sapienza University of Rome
    Rome, Lazio 185, Italy
    Recruiting
    • Site Contact · Contact
    • Salvatore Oliva · Principal investigator
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, Lombardy 20900, Italy
    Terminated

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria A Meyer
    Florence, Tuscany 50139, Italy
    Terminated

    Not enrolling at this site — choose another above.

  • Universita degli Studi di Padova
    Padova, Veneto 35122, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Kurume University Hospital
    Kurume-Shi, Hukuoka 830-0011, Japan
    Recruiting
    • Site Contact · Contact
    • Tatsuki Mizuochi · Principal investigator
  • Japanese Red Cross Kumamoto Hospital
    Kumamoto, Kumamoto 861-8520, Japan
    Recruiting
    • Site Contact · Contact
    • Yugo Takaki · Principal investigator
  • Saitama Children's Medical Center-1397-1 yamane
    Hidaka, Saitama 330-8777, Japan
    Recruiting
    • Site Contact · Contact
    • Itaru Iwama · Principal investigator
  • Juntendo University Hospital
    Bunkyo-Ku, Tokyo 113-8431, Japan
    Recruiting
    • Site Contact · Contact
    • Takahiro Kudo · Principal investigator
  • National Center for Child Health and Development
    Setagaya-Ku, Tokyo 157-8535, Japan
    Recruiting
    • Site Contact · Contact
    • Katsuhiro Arai · Principal investigator
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
    Kaunas, Kaunas County LT-50161, Lithuania
    Withdrawn

    Not enrolling at this site — choose another above.

  • Vilnius University Hospital Santaros Klinikos
    Vilnius, Vilnius County 8406, Lithuania
    Withdrawn

    Not enrolling at this site — choose another above.

  • Uniwersytecki Szpital Dzieciecy w Krakowie
    Krakow, Lesser Poland Voivodeship 30-663, Poland
    Recruiting
    • Site Contact · Contact
    • Kinga Kowalska-Duplaga · Principal investigator
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu-ul.Ludwika Pasteura 4
    Wroclaw, Lower Silesian Voivodeship 50-369, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, Masovian Voivodeship 04-501, Poland
    Recruiting
    • Site Contact · Contact
    • Monika Meglicka · Principal investigator
  • Instytut Pomnik Centrum Zdrowia Dziecka
    Warsaw, Masovian Voivodeship 04-736, Poland
    Recruiting
    • Site Contact · Contact
    • Jaroslaw Kierkus · Principal investigator
  • Korczowski Bartosz, Gabinet Lekarski
    Rzeszów, Podkarpackie Voivodeship 35-302, Poland
    Recruiting
    • Site Contact · Contact
    • Bartosz Korczowski · Principal investigator
  • Copernicus Podmiot Leczniczy Sp. z o.o. - al. Jana Pawla II 50
    Gdansk, Pomeranian Voivodeship 80-803, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Spsk Nr 6 Sum W Katowicach
    Katowice, Silesian Voivodeship 40-752, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Twoja Przychodnia SCM - Slowackiego
    Szczecin, West Pomeranian Voivodeship 71-434, Poland
    Recruiting
    • Site Contact · Contact
    • Beata Gawdis-Wojnarska · Principal investigator
  • SPZOZ Centralny Szpital Kliniczny UM w Lodzi - ul. Pomorska 251
    Lodz, 91-738, Poland
    Recruiting
    • Site Contact · Contact
    • Ewa Toporowska-Kowalska · Principal investigator
  • Instytut Centrum Zdrowia Matki Polki
    Lodz, Łódź Voivodeship 93-338, Poland
    Recruiting
    • Site Contact · Contact
    • Elzbieta Czkwianianc · Principal investigator
  • Narodny ustav detskych chorob
    Bratislava, 833 40, Slovakia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Kyungpook National University Chilgok hospital
    Daegu, Daegu Gwang'yeogsi 41404, South Korea
    Recruiting
    • Site Contact · Contact
    • Ben Kang · Principal investigator
  • Gachon University Gil Medical Center
    Incheon, Incheon Gwang'yeogsi 21565, South Korea
    Terminated

    Not enrolling at this site — choose another above.

  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
    • Site Contact · Contact
    • Jin Soo Moon · Principal investigator
  • Samsung Medical Center
    Seoul, 6351, South Korea
    Recruiting
    • Site Contact · Contact
    • Yon-Ho Choe · Principal investigator
  • Hospital de Sagunto
    Sagunto, Valencia 46520, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Sant Joan de Deu - PIN
    Barcelona, 8950, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Infantil Universitario Nino Jesus - PIN
    Madrid, 28009, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Regional Universitario de Malaga Hospital Materno-Infantil
    Málaga, 29011, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Universitario Virgen del Rocio - PPDS
    Seville, 41013, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Great Ormond Street Hospital
    London, London, City of WC1N 3AJ, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • Noahs Ark Childrens Hospital for Wales - PIN
    Cardiff, South Glamorgan CF14 4XW, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • King's College Hospital
    London, Surrey SE5 9RS, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • Birmingham Women's and Children's NHS Foundation Trust
    Birmingham, Warwickshire B4 6NH, United Kingdom
    Recruiting
    • Site Contact · Contact
    • Rafeeq Muhammed · Principal investigator
  • Barts Health NHS Trust - PPDS
    London, E1 1BB, United Kingdom
    Not yet recruiting
    • Site Contact · Contact
    • Sandhia Naik · Principal investigator
  • Royal Manchester Children's Hospital - PPDS - PIN
    Manchester, M27 4HA, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Feb 2033, 116 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 116 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 5, 2022
StartActual
May 16, 2023
Primary completionEst.
Feb 7, 2033
CompletionEst.
Feb 7, 2033
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05442567
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
May 16, 2023
Primary completion
Feb 7, 2033 (estimated)
Completion
Feb 7, 2033 (estimated)
Last update
May 7, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion